Effect of a novel interleukin-5 receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into the airway of BDF1 mice.
A newly synthesized compound, YM-90709, 2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline, was previously reported to specifically inhibit the binding of interleukin-5 (IL-5) to its receptor (R) on human eosinophils. In this study, the intravenous injection of YM-90709 inhibited antigen-induced infiltration of eosinophils into the bronchoalveolar lavage fluid (BALF) of BDF1 mice, with an ED(50) value of 0.050mg/kg. Anti-murine IL-5 monoclonal antibody (mAb) also inhibited the infiltration of eosinophils with an ED(50) value of 0.035mg/kg. These results indicate that YM-90709, which is a novel IL-5R antagonist, inhibits antigen-induced eosinophil recruitment into the airway, the same as anti-IL-5 mAb does.
Morokata
Tatsuaki
T
Inflammation Research Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. morokata@yamanochi.co.jp
Suzuki
Keiko
K
Ida
Kenji
K
Yamada
Toshimitsu
T
D000818:Animals; D000941:Antigens / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects* / Q000276:immunology; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology; D007211:Indoles / Q000494:pharmacology*; D051379:Mice; D011810:Quinoxalines / Q000494:pharmacology*; D018123:Receptors, Interleukin / Q000037:antagonists & inhibitors*; D053649:Receptors, Interleukin-5; D012137:Respiratory System / Q000187:drug effects* / Q000276:immunology
C475470:2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo(7,8)indolizino (2,3-b)quinoxaline; D000941:Antigens; D007211:Indoles; D011810:Quinoxalines; D018123:Receptors, Interleukin; D053649:Receptors, Interleukin-5